TriangleCD79b-19 CAR T cells (NCT06026319)
CD79b-19 CAR T cells trial for Non-hodgkin Lymphoma (NCT06026319). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for relapsed or refractory non Hodgkin lymphoma, in adults.
The idea: bivalent CAR T cells that aim at two targets, CD79b and CD19, instead of one. White blood cells are collected, then three days of chemotherapy lower the number of lymphocytes, then the CAR T cells are given by vein in a single infusion.
This phase 1 study plans 24 patients and tracks side effects and dose limiting toxicity. At Massachusetts General Hospital in Boston, Matthew Frigault leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.